| Article | |
| Title | Folate Receptor Targeted Alpha-Therapy Using Terbium-149 |
| Author(s) | Müller, Cristina (PSI, Villigen) ; Reber, Josefine (PSI, Villigen) ; Haller, Stephanie (PSI, Villigen) ; Dorrer, Holger (PSI, Villigen ; U. Bern (main)) ; Köster, Ulli (Laue-Langevin Inst.) ; Johnston, Karl (CERN) ; Zhernosekov, Konstantin (PSI, Villigen) ; Türler, Andreas (PSI, Villigen ; U. Bern (main)) ; Schibli, Roger (PSI, Villigen ; ETH, Zurich (main)) |
| Publication | 2014 |
| In: | Pharmaceuticals 7 (2014) 353-365 |
| DOI | 10.3390/ph7030353 |
| Subject category | Health Physics and Radiation Effects ; Other Fields of Physics |
| Accelerator/Facility, Experiment | CERN ISOLDE |
| Abstract | Terbium-149 is among the most interesting therapeutic nuclides for medical applications. It decays by emission of short-range α-particles (Eα = 3.967 MeV) with a half-life of 4.12 h. The goal of this study was to investigate the anticancer efficacy of a 149Tb-labeled DOTA-folate conjugate (cm09) using folate receptor (FR)-positive cancer cells in vitro and in tumor-bearing mice. 149Tb was produced at the ISOLDE facility at CERN. Radiolabeling of cm09 with purified 149Tb resulted in a specific activity of 1.2 MBq/nmol. In vitro assays performed with 149Tb-cm09 revealed a reduced KB cell viability in a FR-specific and activity concentration-dependent manner. Tumor-bearing mice were injected with saline only (group A) or with 149Tb-cm09 (group B: 2.2 MBq; group C: 3.0 MBq). A significant tumor growth delay was found in treated animals resulting in an increased average survival time of mice which received 149Tb-cm09 (B: 30.5 d; C: 43 d) compared to untreated controls (A: 21 d). Analysis of blood parameters revealed no signs of acute toxicity to the kidneys or liver in treated mice over the time of investigation. |
| Copyright/License | publication: © 2014-2025 The Author(s) (License: CC-BY-3.0) |
Record created 2016-03-07, last modified 2022-08-10
